Live
Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsIlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo FinanceFierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.stFierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetesClinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
BioWorld 18. Jan. 2026

Immunitybio’s CAR-NK shows complete responses in Waldenström’s

Immunitybio’s CAR-NK shows complete responses in Waldenström’s

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.